Optimal Combination of Biomarkers to Improve the Predictive Value of Immunotherapeutic Response in Non-Small Cell Lung Cancer

The clinical relevance of current biomarkers predicting response to immuno-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients remain inconclusive. Therefore, there is an urgent need for appropriate strategies and reliable predictors. Like combination therapy, biomarker testing is also trying to integrate cancer-immune systems through a multimodality approach rather than a single test.